Survival for adolescent and young adult leukemia survivors remained below general population at up to 30 years of follow-up<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 13, 2022 (HealthDay News) — Adolescent and young adult (AYA) leukemia survivors have increased mortality rates, even decades after survival, according to a study published online May 13 in Cancer Epidemiology, Biomarkers & Prevention<\/em>.<\/p>\n Amy M. Berkman, M.D., from the Duke University School of Medicine in Durham, North Carolina, and colleagues assessed long-term outcomes of AYA acute leukemia five-year survivors. The impacts of diagnosis age, sex, race\/ethnicity, socioeconomic status, and decade of diagnosis on long-term survival were examined for 1,938 AYA acute lymphoblastic leukemia (ALL) survivors and 2,350 AYA acute myeloid leukemia (AML) survivors diagnosed between 1980 and 2009.<\/p>\n The researchers found that the 10-year survival was 87 and 89 percent for ALL and AML survivors, respectively, and 99 percent for the general population. At up to 30 years of follow-up, survival for AYA leukemia survivors remained below that of the age-adjusted general population. The most common cause of death in early survivorship was primary cancer mortality, while in later decades of follow-up, noncancer causes of death became more prevalent. Significantly worse survival was seen for male versus female AML survivors (survival time ratio, 0.61).<\/p>\n “These patients go through so many challenges during their cancer treatment, and it also appears that they’re going through many more challenges during survivorship,” a coauthor said in a statement. “For example, the mortality of AML survivors continues to increase many decades posttreatment.”<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n